# Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center

> **NCT02502396** · — · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 265 (actual)

## Conditions studied

- Cancer
- Deep-vein Thrombosis of the Lower and Upper Extremities
- Pulmonary Embolism
- Non-valvular Atrial Fibrillation

## Interventions

- **OTHER:** Retrospective Chart Review

## Key facts

- **NCT ID:** NCT02502396
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-28
- **Primary completion:** 2022-03-15
- **Final completion:** 2022-03-15
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2022-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02502396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02502396, "Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02502396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*